This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for Jan 19, 2021
by Zacks Equity Research
This week will be significant both politically and economically as President elect Joe Biden will formally take charge of the U.S. President on Jan 20.
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
by Zacks Equity Research
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
Stock Market News for Jan 18, 2021
by Zacks Equity Research
Wall Street closed lower on Friday on concerns regarding slow vaccination process and mixed economic data.
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
by Zacks Equity Research
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
by Zacks Equity Research
AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.
Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids
by Zacks Equity Research
FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues
by Zacks Equity Research
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.
Why Pfizer (PFE) Could Beat Earnings Estimates Again
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sarepta (SRPT) Inks New Gene Editing Research Collaboration
by Zacks Equity Research
Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.86, marking a -0.86% move from the previous day.
Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $37.18, moving -1.56% from the previous trading session.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
COVID-19 Vaccine Production to Ramp Up
by Zacks Equity Research
COVID-19 Vaccine Production to Ramp Up
Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study
by Zacks Equity Research
Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.
Covid-19 Vaccinations Promise to Ramp Up
by Mark Vickery
Guidance for the end of 2020 was to have 20 million Americans with the first half of the two-injection immunization treatment; as of now, only around 9 million Americans have received the first dose.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $37.77, moving +1.72% from the previous trading session.
4 Reasons for Bank ETFs to Win in 2021
by Sanghamitra Saha
Bank ETFs should stay strong in the coming days on the back of cheaper valuation, Fed's signal for buybacks, Democrat's control over Senate and spike in bond yields.
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
by Zacks Equity Research
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
Racing Against Time: Covid-19 vs. Vaccines
by Mark Vickery
This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
by Zacks Equity Research
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.
What Will Be the Main Economic Drivers in 2021?
by John Blank
With 2020 in the rear-view mirror, we are leaving behind us a plethora of events that affected and shaped our society and economy.
A New Year: Value or Growth? Zacks JAN 2021 Strategy
by John Blank
We had four strong sectors this month, which is bullish. Consumer Discretionary was one of those top areas again this month. COVID has a trifecta of strong spending spots that hit home again. Two internationally exposed sectors -- Materials and Industrials -- also came in at the top, as well.
CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.